UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

Annals of oncology, 2020-12, Vol.31 (12), p.1725-1733

2020

Volltextzugriff (PDF)

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Annals of oncology, 2018-03, Vol.29 (3), p.700-706

2018

Volltextzugriff (PDF)

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

Annals of oncology, 2018-10, Vol.29 (10), p.2092-2097

2018

Volltextzugriff (PDF)

Phase 2 Trial of Afatinib Sequenced With Concurrent Chemo/Radiation in EGFR-Mutant Non-Small Cell Lung Cancer: Initial Feasibility and Response Analysis

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E455-E455

2016

Volltextzugriff (PDF)

FMISO-PET as Biomarker of Early Response to Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2013-10, Vol.87 (2), p.S645-S646

2013

Volltextzugriff (PDF)

Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy

International journal of radiation oncology, biology, physics, 2017-05, Vol.98 (1), p.220-220

2017

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor (EGFR)-Mediated Adverse Events (AEs) in Patients (pts) With EGFR -Mutation Positive ( EGFR M+) Non-Small Cell Lung Cancer (NSCLC) Treated With Afatinib (A)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S41-S41

2014

Volltextzugriff (PDF)

First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials

European journal of cancer (1990), 2017-02, Vol.72, p.S176-S177

2017

Volltextzugriff (PDF)

3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement

European journal of cancer (1990), 2015-09, Vol.51, p.S598-S598

2015

Volltextzugriff (PDF)

3104 Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M

European journal of cancer (1990), 2015-09, Vol.51, p.S636-S636

2015

Volltextzugriff (PDF)

3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies

European journal of cancer (1990), 2015-09, Vol.51, p.S640-S640

2015

Volltextzugriff (PDF)

3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial

European journal of cancer (1990), 2015-09, Vol.51, p.S637-S637

2015

Volltextzugriff (PDF)

3088 Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test

European journal of cancer (1990), 2015-09, Vol.51, p.S628-S628

2015

Volltextzugriff (PDF)

Acquired Resistance to Afatinib in EGFR-Mutant Lung Cancer

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S43-S44

2014

Volltextzugriff (PDF)

Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S6-S7

2014

Volltextzugriff (PDF)

Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer: Significance of Mutations in EGFR, ALK, or KRAS on Radiation Therapy Response and Survival

International journal of radiation oncology, biology, physics, 2013-10, Vol.87 (2), p.S51-S51

2013

Volltextzugriff (PDF)

Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S36-S36

2014

Volltextzugriff (PDF)

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S34-S34

2014

Volltextzugriff (PDF)

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

European journal of cancer (1990), 2014-11, Vol.50, p.199-199

2014

Volltextzugriff (PDF)

82IN - Molecular Mechanisms of Acquired Resistance to Kinase Inhibitors

Annals of oncology, 2012-09, Vol.23, p.ix51-ix51

Sequist, L.V.

2012

Volltextzugriff (PDF)

Molecular Mechanisms of Acquired Resistance to Kinase Inhibitors

Annals of oncology, 2012-09, Vol.23, p.ix51

Sequist, L.V.

2012

Volltextzugriff (PDF)

482 Relationship Between Tumor MET Expression and Clinical Outcomes in Cancer Patients Treated with Tivantinib

European journal of cancer (1990), 2012-11, Vol.48, p.149-149

2012

Volltextzugriff (PDF)

32 LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S11-S11

2013

Volltextzugriff (PDF)

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Annals of oncology, 2016-11, Vol.27 (11), p.2103-2110

2016

Volltextzugriff (PDF)

KRAS Mutation is Associated with Decreased Overall Survival after Thoracic Radiation Therapy in Patients with Locally Advanced Non-small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S36-S36

2010

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(67)

Sprache

Englisch
(67)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(20)
Radiology
(10)
Humans
(7)
Life Sciences & Biomedicine
(7)
Oncology
(7)
Science & Technology
(7)
Lung Neoplasms - Drug Therapy
(6)
Lung Neoplasms - Genetics
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Carcinoma, Non-Small-Cell Lung - Genetics
(5)
Adult
(4)
Aged
(4)
Erbb Receptors - Genetics
(4)
Female
(4)
Male
(4)
Middle Aged
(4)
Mutation
(4)
Biomarkers, Tumor - Genetics
(3)
Nsclc
(3)
Adenocarcinoma - Drug Therapy
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(39)
Journals@Ovid Ovid Full Text
(37)
Ingenta
(29)
ScienceDirect Pay Per View(PPV) Titles
(29)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(28)
IngentaConnect Journals
(20)
MEDLINE
(7)

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(29)
International Journal Of Radiation Oncology, Biology, Physics
(18)
European Journal Of Cancer
(9)
Journal Of Thoracic Oncology
(8)
Esmo Open
(1)
European Journal Of Cancer Supplements
(1)
Lung Cancer
(1)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

Phase 2 Trial of Afatinib Sequenced With Concurrent Chemo/Radiation in EGFR-Mutant Non-Small Cell Lung Cancer: Initial Feasibility and Response Analysis

FMISO-PET as Biomarker of Early Response to Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy

Epidermal Growth Factor Receptor (EGFR)-Mediated Adverse Events (AEs) in Patients (pts) With EGFR -Mutation Positive ( EGFR M+) Non-Small Cell Lung Cancer (NSCLC) Treated With Afatinib (A)

First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials

3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement

3104 Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M

3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies

3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial

3088 Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test

Acquired Resistance to Afatinib in EGFR-Mutant Lung Cancer

Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy

Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer: Significance of Mutations in EGFR, ALK, or KRAS on Radiation Therapy Response and Survival

Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

82IN - Molecular Mechanisms of Acquired Resistance to Kinase Inhibitors

Molecular Mechanisms of Acquired Resistance to Kinase Inhibitors

482 Relationship Between Tumor MET Expression and Clinical Outcomes in Cancer Patients Treated with Tivantinib

32 LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

KRAS Mutation is Associated with Decreased Overall Survival after Thoracic Radiation Therapy in Patients with Locally Advanced Non-small Cell Lung Cancer

Suchergebnisse filtern